Comprehensive DNA Methylation Profiling in Crohn's Disease

Comprehensive DNA Methylation Profiling of Inflammatory and Non-Inflammatory Mucosa in Crohn's Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03272152

Enrollment

Registered

2017-09-05

Start date

2017-01-01

Completion date

2017-09-30

Last updated

2017-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, Illumina Human Methylation 850k BeadChip, Methylation

Brief summary

Previous studies have indicated that abnormal DNA methylation frequently occurs in the mucosa in Crohn's disease. Comprehensive DNA methylation profiling of the inflamed and non-inflamed ileal mucosa of patients with Crohn's disease was performed. Genome-wide DNA methylation was determined using the Illumina HumanMethylation 850k BeadChip.

Interventions

GENETICGenome-wide DNA methylation

Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Active Crohn's disease(CDAI score≥ 150)

Exclusion criteria

* No ileal lesions * Under treatment of immunomodulators, biologic agents or steroids

Design outcomes

Primary

Measure	Time frame	Description
Intestinal inflammation under colonoscopy	Jan 2017 to Sep 2017	Intestinal ulcer or enteritisis observed under colonoscopy

Secondary

Measure	Time frame	Description
CDAI	Jan 2017 to Sep 2017	Crohns Disease Activity Index is measured.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026